MAP6D1

Across TCGA pan-cancer cohorts, MAP6D1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAP6D1 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MAP6D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP6D1 expression acts as an unfavorable survival marker.

STAD are the cancer types where MAP6D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MAP6D1–STAD (OS)

Open the STAD breakdown →